Pages
- Cookie Policy
- Home
- Who We Are
- What We Do
- Thought Leadership
- News & Events
- Careers
- Privacy Policy
- iValue Suite®
- MCDA
- ACE
- STC-MAIC
- DICE
- ARCHES
- Early Access
- Surrogate Endpoints
- A New EU HTA Directive
- DICE Demos
- Evidence Synthesis and Modeling
- Integrated Scientific Advice
- Oncology Value Frameworks Tool
- Patient-Focused Drug Development Guidance: Key Highlights From FDA’s Second Public Meeting
- Patient-Focused Drug Development Guidance: Key Highlights From FDA’s Second Public Meeting
- Precision and Transformative Medicine – Request Additional Information
- Precision and Transformative Medicine Center of Excellence
- Precision and Transformative Medicine Focus Areas
- REWARD
- Thank You for Downloading Our Presentation
- White Paper: Adapting an Existing Instrument for a Rare Disease: A Valuable Resource within Your Reach
- White Paper: Advancing Healthcare through Innovation and Collaboration
- White Paper: Can Early Collaboration between Multiple European Stakeholders Increase Access for Patients Living with Rare Diseases?
- White Paper: Clinical Outcome Assessment Selection for Rare Disease Trial Programs
- White Paper: Enhancing Patient Centricity of HTA: Opportunities in Europe
- White Paper: Evidence Requirements for Orphan Drugs from a Payer Perspective: How Can Early Scientific Advice Help?
- White Paper: FDA Updates Draft Guidance on Rare Diseases: Some Key Takeaways You Need to Know
- White Paper: Health Economics in China: Changing Pharmaceutical Pricing and Reimbursement
- White Paper: How Social Media Can Be Used to Understand What Matters to People with Rare Diseases
- White Paper: Increase Study Awareness and Patient Engagement with the Use of Branded Study Materials
- White Paper: More Evidence Needed for Orphan Drugs in Germany: A Hurdle for Access and an Opportunity for Real-World Evidence
- White Paper: Natural History Studies in Rare Diseases and Genetic Biomarkers
- White Paper: Patient Engagement in Clinical Trial Protocol Design and Recruitment Strategies: What Does It Mean for Orphan Drug Manufacturers?
- White Paper: Patient Preferences in Health Technology Assessment in Europe: Recent Advances and Future Potential
- White Paper: Policy Trends Update: CADTH Launches Parallel Scientific Advice Programs with NICE and Health Canada
- White Paper: Pragmatic Randomized Trials: Considerations for Design and Implementation
- White Paper: Protocol Design in Real-World Evidence: The Indispensable Link Between Strategic Need and Study Execution
- White Paper: Rare Disease Treatments Aren’t So Rare Any More
- White Paper: Registries in Rare Disease Research: Approaches to Optimize Success
- White Paper: Research Operations for Secondary Use of Clinical Sites’ EMR
- White Paper: The Growing Influence of the Institute of Clinical and Economic Review on Payer Decisions in the US
- White Paper: The Growing Need for Real-World Evidence in Medical Devices
- White Paper: The Role of Integrated Scientific Advice for the Early Determination of RWE Requirements in HTA and Payer Assessments
- White Paper: Virtual Trials and Real-World Evidence Data Collection: Identifying Core Needs and Defining “Virtual Trials”